Alto Neuroscience (ANRO) News Today $2.24 -0.01 (-0.22%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$2.29 +0.04 (+2.00%) As of 04/17/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAlto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the cApril 17 at 6:23 AM | marketbeat.comWhat is HC Wainwright's Forecast for ANRO Q1 Earnings?Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Alto Neuroscience in a research note issued on Monday, April 7th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.45) per share for the quarter. HC WainwrighApril 12, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for ANRO Q1 Earnings?April 12, 2025 | americanbankingnews.comAlto Neuroscience (NYSE:ANRO) Now Covered by HC WainwrightHC Wainwright began coverage on Alto Neuroscience in a research report on Monday. They issued a "buy" rating and a $10.00 price target on the stock.April 9, 2025 | marketbeat.comHC Wainwright Begins Coverage on Alto Neuroscience (NYSE:ANRO)April 9, 2025 | americanbankingnews.comAlto Neuroscience initiated with a Buy at H.C. WainwrightApril 8, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Alto Neuroscience (ANRO) with Buy RecommendationApril 8, 2025 | msn.comJonesTrading Sticks to Its Buy Rating for Alto Neuroscience, Inc. (ANRO)March 25, 2025 | markets.businessinsider.comBuy Rating Reaffirmed for Alto Neuroscience, Inc. Amid Promising Pipeline and Upcoming Data ReadoutsMarch 24, 2025 | tipranks.comWhat is Wedbush's Estimate for ANRO FY2029 Earnings?Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Stock analysts at Wedbush issued their FY2029 earnings per share estimates for Alto Neuroscience in a research report issued on Thursday, March 20th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($2.88) fMarch 24, 2025 | marketbeat.comWhat is William Blair's Forecast for ANRO Q1 Earnings?Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Analysts at William Blair issued their Q1 2026 EPS estimates for Alto Neuroscience in a report released on Friday, March 21st. William Blair analyst M. Minter expects that the company will post earnings of ($0.53) per share for the quarter. WillMarch 24, 2025 | marketbeat.comAnalysts Offer Insights on NA Companies: Reddit Inc Class A (RDDT) and Alto Neuroscience, Inc. (ANRO)March 22, 2025 | markets.businessinsider.comALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly EarningsMarch 22, 2025 | nasdaq.comAlto Neuroscience, Inc. (ANRO) Gets a Hold from WedbushMarch 22, 2025 | markets.businessinsider.comAlto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of "Moderate Buy" by AnalystsShares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buyMarch 22, 2025 | marketbeat.comAlto Neuroscience's (ANRO) Outperform Rating Reaffirmed at William BlairWilliam Blair restated an "outperform" rating on shares of Alto Neuroscience in a research note on Friday.March 22, 2025 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Expectations By $0.09 EPSAlto Neuroscience (NYSE:ANRO - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.09.March 21, 2025 | marketbeat.comAlto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business HighlightsMarch 20, 2025 | gurufocus.comAlto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on ThursdayAlto Neuroscience (NYSE:ANRO) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Trading Up 8.8% - Should You Buy?Alto Neuroscience (NYSE:ANRO) Stock Price Up 8.8% - What's Next?March 6, 2025 | marketbeat.comAlto Neuroscience rises 25.0%March 4, 2025 | markets.businessinsider.com1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in MarchMarch 4, 2025 | msn.comAlto Neuroscience rises 19.6%March 3, 2025 | markets.businessinsider.comAlto Neuroscience to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | businesswire.comUSPTO grants Alto Neuroscience patent for MDD treatment covering ALTO-300February 19, 2025 | markets.businessinsider.comAlto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram BiomarkerFebruary 19, 2025 | businesswire.comPleasing Signs As A Number Of Insiders Buy Alto Neuroscience StockFebruary 18, 2025 | finance.yahoo.comTD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)February 13, 2025 | markets.businessinsider.comAlto Neuroscience announces interim analysis from ALTO-300 trialFebruary 12, 2025 | markets.businessinsider.comStifel maintains Buy on Alto Neuroscience stock, $10 targetFebruary 12, 2025 | msn.comAlto Neuroscience advances trial for depression treatmentFebruary 12, 2025 | msn.comANRO stock touches 52-week low at $3.23 amid market challengesFebruary 11, 2025 | msn.comStifel Nicolaus Sticks to Their Buy Rating for Alto Neuroscience, Inc. (ANRO)February 10, 2025 | markets.businessinsider.comAlto Neuroscience files $300M mixed securities shelfFebruary 4, 2025 | markets.businessinsider.comAlto Neuroscience announces $75 million ATM offeringFebruary 4, 2025 | msn.comAlto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from AnalystsAlto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has received an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and five have given a buy ratingFebruary 1, 2025 | marketbeat.comAlto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of "Moderate Buy" by BrokeragesShares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and five have issuedJanuary 7, 2025 | marketbeat.comAlto Neuroscience, Inc. (NYSE:ANRO) Stock Holdings Increased by Geode Capital Management LLCGeode Capital Management LLC grew its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 148.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 469,988 shares of the company's stocJanuary 5, 2025 | marketbeat.comAlto Neuroscience, Inc. (NYSE:ANRO) Shares Purchased by State Street CorpState Street Corp raised its holdings in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 123.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 236,857 shares of the company's stock afJanuary 1, 2025 | marketbeat.comFranklin Resources Inc. Purchases 595,673 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)Franklin Resources Inc. increased its position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 95.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,220,712 shares of the company's stock afterDecember 21, 2024 | marketbeat.comAlto Neuroscience, Inc. (ANRO) Receives a Buy from JonesTradingDecember 17, 2024 | markets.businessinsider.comJones Trading Initiates Coverage of Alto Neuroscience (ANRO) with Buy RecommendationDecember 17, 2024 | msn.comAlto Neuroscience, Inc. (NYSE:ANRO) Short Interest UpdateAlto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) was the target of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 4,080,000 shares, a decrease of 12.4% from the November 15th total of 4,660,000 shares. Based on an average daily volume of 777,200 shares, the days-to-cover ratio is currently 5.2 days. Currently, 18.6% of the shares of the stock are sold short.December 15, 2024 | marketbeat.comAlto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and five have assigned a buy rating toDecember 13, 2024 | marketbeat.comAlto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of NeuropsychopharmacologyDecember 11, 2024 | finance.yahoo.comJennison Associates LLC Acquires 370,612 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)Jennison Associates LLC lifted its stake in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 80.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 832,290 shares of the company's stock after acquiring an additiNovember 23, 2024 | marketbeat.comFY2024 EPS Estimate for Alto Neuroscience Boosted by AnalystAlto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Stock analysts at William Blair increased their FY2024 EPS estimates for Alto Neuroscience in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Minter now forecasts that the company will post earnings per share ofNovember 18, 2024 | marketbeat.comFY2024 EPS Estimates for Alto Neuroscience Cut by WedbushAlto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Research analysts at Wedbush decreased their FY2024 EPS estimates for shares of Alto Neuroscience in a research note issued on Wednesday, November 13th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($2.60November 15, 2024 | marketbeat.comPotential Catalysts and Strategic Focus: Analyzing Alto Neuroscience’s Upcoming Trials and Precision Psychiatry ApproachNovember 14, 2024 | markets.businessinsider.comAlto Neuroscience price target lowered to $10 from $32 at StifelNovember 14, 2024 | markets.businessinsider.com Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address ANRO Media Mentions By Week ANRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANRO News Sentiment▼1.080.49▲Average Medical News Sentiment ANRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANRO Articles This Week▼42▲ANRO Articles Average Week Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Solid Biosciences News Today Alpha Teknova News Today Septerna News Today enGene News Today Atea Pharmaceuticals News Today Esperion Therapeutics News Today Acelyrin News Today Candel Therapeutics News Today Aurora Cannabis News Today Palvella Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANRO) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
